News >

Pembrolizumab/Chemo Combo Misses OS Endpoint in Advanced Gastric/GEJ Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 26, 2019

The combination of pembrolizumab (Keytruda) and chemotherapy did not improve overall survival (OS) or progression-free survival (PFS) compared with standard chemotherapy alone for the frontline treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to topline findings of the phase III KEYNOTE-062 trial.1

 

References

  1. Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Merck. Published April 25, 2019. https://bit.ly/2IXZtwG. Accessed April 25, 2019.
  2. FDA Approves Merck’s KEYTRUDA (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1). Merck. http://bit.ly/2wberGs. Accessed September 22, 2017.
  3. Fuchs CS, Doi T, Jang RW-J, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017;35 (suppl; abstr 4003).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x